California State Teachers Retirement System Has $2.36 Million Holdings in Pacira Pharmaceuticals, Inc. (PCRX)

California State Teachers Retirement System trimmed its holdings in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 9.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,886 shares of the company’s stock after selling 6,690 shares during the period. California State Teachers Retirement System owned about 0.16% of Pacira Pharmaceuticals worth $2,361,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Oppenheimer Asset Management Inc. acquired a new position in shares of Pacira Pharmaceuticals in the 2nd quarter valued at approximately $114,000. Cubist Systematic Strategies LLC raised its position in shares of Pacira Pharmaceuticals by 121.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after purchasing an additional 1,752 shares in the last quarter. QS Investors LLC acquired a new position in shares of Pacira Pharmaceuticals in the 2nd quarter valued at approximately $157,000. Ameritas Investment Partners Inc. raised its position in shares of Pacira Pharmaceuticals by 9.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after purchasing an additional 302 shares in the last quarter. Finally, Spectrum Management Group Inc. acquired a new position in shares of Pacira Pharmaceuticals in the 3rd quarter valued at approximately $166,000.

In related news, CEO David M. Stack sold 58,885 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at approximately $6,102,347.76. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mark A. Kronenfeld bought 1,000 shares of the company’s stock in a transaction on Friday, November 10th. The stock was bought at an average cost of $41.60 per share, for a total transaction of $41,600.00. Following the completion of the transaction, the director now directly owns 6,795 shares of the company’s stock, valued at $282,672. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 98,960 shares of company stock worth $3,868,341. Corporate insiders own 6.60% of the company’s stock.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) opened at $41.50 on Monday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99. The stock has a market capitalization of $1,680.00, a P/E ratio of -31.68 and a beta of 2.20. Pacira Pharmaceuticals, Inc. has a 52-week low of $29.81 and a 52-week high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. The business had revenue of $67.30 million for the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 EPS. research analysts predict that Pacira Pharmaceuticals, Inc. will post -0.85 earnings per share for the current year.

A number of brokerages have issued reports on PCRX. Zacks Investment Research raised Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Tuesday, October 3rd. Needham & Company LLC cut their target price on Pacira Pharmaceuticals from $55.00 to $52.00 and set a “buy” rating on the stock in a research report on Thursday, October 19th. BidaskClub raised Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Wedbush reaffirmed a “buy” rating on shares of Pacira Pharmaceuticals in a research report on Friday, January 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $52.00 target price on shares of Pacira Pharmaceuticals in a research report on Thursday, November 9th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Pacira Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $49.00.

ILLEGAL ACTIVITY NOTICE: “California State Teachers Retirement System Has $2.36 Million Holdings in Pacira Pharmaceuticals, Inc. (PCRX)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://ledgergazette.com/2018/01/15/california-state-teachers-retirement-system-has-2-36-million-holdings-in-pacira-pharmaceuticals-inc-pcrx.html.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply